The value of pharmaceutical outsourcing deals rose from $9.9 billion in 2014 to nearly $17.6 billion this year, according to research and consulting firm GlobalData.
The company attributes the rise in value primarily to a drastic increase in merger and acquisition deals, which has nearly doubled from $5.5 billion in 2014 to nearly $12 billion to October this year.
In an article for Arena International’s Clinical Trial Year Book 2016 (ADD LINK), Adam Dion, GlobalData’s senior healthcare industry analyst, said it puts the sector on track for a record-breaking year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze